Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Achieve Life Sciences Inc ACHV

Healthcare Biotechnology
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of... see more

Recent & Breaking News (NDAQ:ACHV)

Achieve Life Sciences Announces Appointment of Dr. Vaughn Himes to Board of Directors

GlobeNewswire March 14, 2022

Achieve Life Sciences Announces Expansion of Manufacturing & Quality Operations Team and Granting of Inducement Award

GlobeNewswire March 11, 2022

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update

GlobeNewswire March 10, 2022

Achieve Life Sciences Announces Participation in March Investor Conferences

GlobeNewswire March 8, 2022

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022

GlobeNewswire February 24, 2022

Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award

GlobeNewswire February 3, 2022

Achieve Life Sciences Announces Participation in February Investor Conferences

GlobeNewswire February 2, 2022

36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022

Accesswire January 28, 2022

Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

GlobeNewswire January 25, 2022

Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference

GlobeNewswire January 6, 2022

Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

GlobeNewswire January 4, 2022

Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development

GlobeNewswire December 22, 2021

Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation

GlobeNewswire November 23, 2021

Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)

GlobeNewswire November 22, 2021

Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development

GlobeNewswire November 9, 2021

Achieve Life Sciences Announces Participation in November Investor Conferences

GlobeNewswire November 4, 2021

Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline's Second Planned Indication for Nicotine E-cigarette Cessation

GlobeNewswire November 2, 2021

Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021

GlobeNewswire October 26, 2021

Achieve Life Sciences to Participate in Upcoming Investor Conferences

Accesswire September 15, 2021

Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference

Accesswire September 14, 2021